The company is currently conducting clinical studies to validate AlloSure's technology — which underlies its kidney transplant test — in lung transplant patients.
Researchers will first compare liquid with tissue-based tumor profiling before implementing it as a way to enroll patients into the targeted drug trials.
The new center will focus on liquid biopsy technologies for tracking treatment response and for monitoring patients with minimal residual disease.
Researchers used the system to improve a method for analyzing lymph nodes and believe it could improve the care of patients with these and other early-stage cancers.
The test is for monitoring treatment response in chronic myeloid leukemia and uses a new Droplet Digital PCR instrument.
The team evaluated BSTs from Norgen, Streck, Roche Diagnostics and PreAnalytix, and said Norgen's was the best in terms of genetic material storage.
As part of the agreement, LifeLabs will serve as an exclusive distributor for MDxHealth's non-invasive liquid biopsy prostate cancer assay In Canada.
An analyst said the DetermaVu test could potentially be best in class for lung cancer diagnosis and that CMS could begin reimbursing for it in late 2020.
The company will use proceeds to support commercialization of its lung cancer liquid biopsy test, and to fund studies to cement reimbursement and adoption.
Biocept is offering 6.25 million shares of its common stock and warrants to purchase up to 6.25 million shares of the common stock at a combined price $1.20 per share and warrant.
The effort will also help resolve open questions about liquid biopsy sequencing's validity in clinical practice in general.
Based on the results, the UAE-based lab would become Biocept's first customer to use the kits clinically, accepting samples from the Middle East, Africa, and Asia.
In fiscal Q2, the firm's Diagnostics and Genomics revenues were $39.3 million, up 6 percent year over year from $37.1 million.
The test showed 90 percent sensitivity and 75 percent specificity in a 250-patient blinded study, even without the addition of clinical risk information.
The company is now offering 3.6 million shares and warrants to purchase additional shares at an assumed combined price of $2.11 per share and related warrant.
In a clinical study Baylor researchers found that PreSeek, which Natera markets as Vistara, reliably detected dominant disorders in more than 400 pregnancies.
The institutes will send patients samples to Resolution Bioscience, which will sequence circulating tumor DNA to identify the genetic causes of drug resistance.
A team led by researchers at the NHLBI are testing the efficacy of measuring ddcfDNA in blood as a biomarker of chronic rejection for lung transplants.
The qPCR assay measures methylation of six genes and could help doctors identify aggressive vs indolent prostate cancer more accurately than PSA.
The researchers believe using cerebral spinal fluid will enable them to identify brain tumors with a higher sensitivity than with blood samples.
Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.
Wired reports that researchers have shown they could reprogram a DNA-based computer.
Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.
In Science this week: whole-genome sequencing of single sperm cells, and more.